SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Osimertinib will be administered orally at the dose of 80 mg once daily.

Patients who possess oligoresidual disease after 3rd generation EGFR-TKI therapy will be treated with the intent to ablate all residual disease with consolidative SRT. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. TKI will be continued during and after consolidative SRT until disease progression or intolerable toxicity.